CRISPR Therapeutics (CRSP) Tops Q1 EPS by 107c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures muted as oil stays above $100 ahead of earnings
- Oil prices fluctuate on Trump's Russian diesel comments, attacks on Saudi
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($0.67), $1.07 better than the analyst estimate of ($1.74). Revenue for the quarter came in at $100 million versus the consensus estimate of $25.85 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BTIG Downgrades UWM Holdings Corp. (UWMC) to Neutral
- Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
- DHT Holdings reports Q3 2026 TCE earnings of $141,300 per day
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
